Innate Pharma
NASDAQ: IPHA · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Innate Pharma (IPHA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $360000.00 | $-9.28M | $-14.74M | $-5.94M | $-13.45M | $12.99M | $-10.47M | $-10.97M | $-18.13M | $207.91M | $-36.85M | $-48.06M | $-32.53M | $34.92M | $-51.81M | $-58.46M | $-19.15M | $-32.56M | $-6.90M | $-50.67M |
| Capital expenditures | $752000.00 | $1.30M | $1.90M | $511000.00 | $408000.00 | $322000.00 | $1.23M | $433000.00 | $2.34M | $7.40M | $9.39M | $6.03M | $1.43M | $65.40M | $11.28M | $1.33M | $1.12M | $2.35M | $391000.00 | $134474.00 |
| Depreciation | $298000.00 | $536000.00 | $539000.00 | $1.02M | $1.10M | $901000.00 | $839000.00 | $880000.00 | $2.34M | $2.65M | $3.26M | $4.39M | $7.40M | $16.53M | $56.80M | $4.60M | $45.41M | $5.09M | $1.99M | — |
| Stock-based comp | $1.19M | $1.26M | $1.34M | $1.77M | $35000.00 | $219000.00 | — | $325000.00 | $377000.00 | $1.01M | $1.03M | $9.83M | $2.71M | $3.83M | $2.48M | $2.62M | $4.25M | $4.26M | $3.94M | $4.26M |
| Free cash flow | $-392000.00 | $-10.58M | $-16.64M | $-6.45M | $-13.86M | $12.66M | $-11.70M | $-11.40M | $-20.48M | $200.51M | $-46.24M | $-54.09M | $-33.96M | $-30.48M | $-63.09M | $-59.79M | $-20.28M | $-34.91M | $-7.29M | $-50.81M |
| Investing cash flow | $-38.99M | $4.97M | $22.52M | $18.94M | $-289000.00 | $2.44M | $-3.41M | $-958000.00 | $-3.82M | $-122.30M | $60.51M | $-29.46M | $24.28M | $-62.12M | $-13.37M | $-917000.00 | $1.88M | $20.63M | $9.20M | — |
| Financing cash flow | $42.21M | $631000.00 | $623000.00 | $22.56M | $-893000.00 | $-659000.00 | $-2.15M | $19.68M | $47.95M | $3.03M | $-602000.00 | $915000.00 | $61.22M | $77.77M | $-1.14M | $26.82M | $-1.83M | $-1.97M | $-6.01M | — |
| Dividends paid | — | — | — | $1.20M | — | — | — | — | $850000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
Frequently asked questions
What is Innate Pharma's revenue?
Innate Pharma's trailing twelve-month revenue is $9.01M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is IPHA?
In its most recent fiscal year, IPHA ran a gross margin of 100.00%, an operating margin of -1,916.94%, and a net margin of -1,764.51%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does IPHA generate?
IPHA produced $-50.81M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is IPHA's balance sheet healthy?
IPHA holds $28.08M in cash and equivalents against $13.67M in long-term debt, on $-21.69M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.